serabelisib [Ligand Id: 8969] activity data from GtoPdb
Click here for a description of the charts and data table
Please tell us if you are using this feature and what you think!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
| DB | Assay description | Assay Type | Standard value | Standard parameter | Original value | Original units | Original parameter | Reference |
|---|---|---|---|---|---|---|---|---|
| mechanistic target of rapamycin kinase in Human [GtoPdb: 2109] [UniProtKB: P42345] | ||||||||
| GtoPdb | - | - | 5 | pIC50 | <10000 | nM | IC50 | US20130035324 A1. Heterocyclic compounds and uses thereof. (2013) |
| phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha in Human [GtoPdb: 2153] [UniProtKB: P42336] | ||||||||
| GtoPdb | - | - | 7 | pIC50 | <100 | nM | IC50 | US20130035324 A1. Heterocyclic compounds and uses thereof. (2013) |
| phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta in Human [GtoPdb: 2154] [UniProtKB: P42338] | ||||||||
| GtoPdb | - | - | 5 | pIC50 | <10000 | nM | IC50 | US20130035324 A1. Heterocyclic compounds and uses thereof. (2013) |
| phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta in Human [GtoPdb: 2155] [UniProtKB: O00329] | ||||||||
| GtoPdb | - | - | 5 | pIC50 | <10000 | nM | IC50 | US20130035324 A1. Heterocyclic compounds and uses thereof. (2013) |
| phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma in Human [GtoPdb: 2156] [UniProtKB: P48736] | ||||||||
| GtoPdb | - | - | 5 | pIC50 | <10000 | nM | IC50 | US20130035324 A1. Heterocyclic compounds and uses thereof. (2013) |
Our curators have not yet identified this ligand in ChEMBL, but you may find additional data by searching on the ChEMBL site using the ligand's name or structure.
